Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Company profile
Ticker
AVTX
Exchange
Website
CEO
Dr. Garry A. Neil M.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Customers 1st Bancorp, Inc.
SEC CIK
Corporate docs
Subsidiaries
Medgenics Medical (Israel) Ltd. • Aevi Genomic Medicine Europe ...
AVTX stock data
Latest filings (excl ownership)
8-K
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
8 Oct 24
8-K
Other Events
9 Sep 24
8-K
Other Events
4 Sep 24
8-K
Departure of Directors or Certain Officers
14 Aug 24
10-Q
2024 Q2
Quarterly report
12 Aug 24
8-K
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
12 Aug 24
EFFECT
Notice of effectiveness
6 Aug 24
424B3
Prospectus supplement
5 Aug 24
8-K
Other Events
30 Jul 24
S-3/A
Shelf registration (amended)
29 Jul 24
Latest ownership filings
SC 13G
Ikarian Capital, LLC
7 Oct 24
SC 13G
BIOTECHNOLOGY VALUE FUND L P
23 Aug 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
23 Aug 24
SC 13G
Crutcher Patrick J
23 Aug 24
4
Jonathan Goldman
14 Aug 24
4
Mitchell Chan
14 Aug 24
4
June Sherie Almenoff
14 Aug 24
4
AARON KANTOFF
14 Aug 24
4
Samantha Truex
14 Aug 24
4
GILLA KAPLAN
14 Aug 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 93.56 mm | 93.56 mm | 93.56 mm | 93.56 mm | 93.56 mm | 93.56 mm |
Cash burn (monthly) | 5.59 mm | (no burn) | (no burn) | 3.02 mm | 5.43 mm | 2.67 mm |
Cash used (since last report) | 20.97 mm | n/a | n/a | 11.33 mm | 20.38 mm | 10.04 mm |
Cash remaining | 72.59 mm | n/a | n/a | 82.23 mm | 73.18 mm | 83.52 mm |
Runway (months of cash) | 13.0 | n/a | n/a | 27.2 | 13.5 | 31.2 |
Institutional ownership, Q2 2024
15.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 3 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 6.23 mm |
Total shares | 1.49 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Venrock Healthcare Capital Partners III | 1.35 mm | $4.68 mm |
Allostery Investments | 78.26 k | $1.25 mm |
Emerald Bioventures | 58.35 k | $277.00 k |
Key FInancial | 1.00 | $12.00 k |
Activest Wealth Management | 1.00 | $12.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Aug 24 | Jonathan Goldman | RSU Common Stock | Grant | Acquire A | No | No | 0 | 9,500 | 0.00 | 9,500 |
13 Aug 24 | Jonathan Goldman | Stock Option Common Stock | Grant | Acquire A | No | No | 9.88 | 24,600 | 243.05 k | 24,600 |
13 Aug 24 | Mitchell Chan | RSU Common Stock | Grant | Acquire A | No | No | 0 | 9,500 | 0.00 | 9,500 |
13 Aug 24 | Mitchell Chan | Stock Option Common Stock | Grant | Acquire A | No | No | 9.88 | 24,600 | 243.05 k | 24,600 |
13 Aug 24 | June Sherie Almenoff | RSU Common Stock | Grant | Acquire A | No | No | 0 | 9,500 | 0.00 | 9,500 |
13 Aug 24 | June Sherie Almenoff | Stock Option Common Stock | Grant | Acquire A | No | No | 9.88 | 24,600 | 243.05 k | 24,600 |
13 Aug 24 | Aaron Kantoff | RSU Common Stock | Grant | Acquire A | No | No | 0 | 9,500 | 0.00 | 9,500 |
13 Aug 24 | Aaron Kantoff | Stock Option Common Stock | Grant | Acquire A | No | No | 9.88 | 24,600 | 243.05 k | 24,600 |
13 Aug 24 | Samantha Truex | RSU Common Stock | Grant | Acquire A | No | No | 0 | 9,500 | 0.00 | 9,500 |
13 Aug 24 | Samantha Truex | Stock Option Common Stock | Grant | Acquire A | No | No | 9.88 | 24,600 | 243.05 k | 24,600 |